Rigel’s Q1 2026: A Measured Profit Push Amid Pipeline Noise and a Lilly Denouement

Ticker: RIGL. In this report, we parse the EX-99.1 filing and translate the numbers into signals for EPS, revenue forecast, and the road ahead.

Overview

Rigel Pharmaceuticals, Inc. (RIGL) kicked off 2026 with a first-quarter that looks like a company coordinating a growth plan with a practical set of instruments. The press release details total revenues of $58.8 million, broken down into net product sales of $54.9 million and $3.9 million from contract revenues. Net income for the quarter comes in at $8.7 million, a data point investors will eventually translate into earnings per share (EPS) once share counts are factored in for a formal quarterly earnings release.

The release frames a strategic narrative around ongoing commercial momentum, a developing pipeline (notably the R289 program in a Phase 1b study for lower-risk myelodysplastic syndromes), and a commitment to advancing the company’s growth trajectory into 2026 and beyond. The coverage also notes corporate governance moves and a potential change in collaboration dynamics that could influence both near-term cash flows and long-range optionality.

Financial highlights

Total revenues: $58.8 million; net product sales: $54.9 million; contract revenues: $3.9 million.
Net income: $8.7 million for the quarter.
First-quarter net product sales rose 26% versus the prior-year period.
Outlook: 2026 revenue forecast in the range of $275–$290 million; net product sales forecast of $255–$265 million.
Conference call and webcast scheduled for 4:30 p.m. Eastern Time.
Key products highlighted: TAVALISSE (fostamatinib disodium hexahydrate), GAVRETO (pralsetinib), and REZLIDHIA (olutasidenib).

Analysts will be converting these figures into EPS estimates and a broader earnings narrative, but the release itself does not publish an EPS number. The revenue forecast provides a line in the sand, and the mix—dominant net product sales with smaller contract revenues—shapes the near-term profitability story.

Pipeline and strategic moves

Beyond the quarterly math, Rigel emphasizes pipeline progress, including the ongoing Phase 1b dose-expansion for R289 in lower-risk MDS, with a plan to select the recommended Phase 2 dose in the second half of 2026. This cadence—enrollment progress followed by dose selection—serves as the narrative bridge from current profitability to future growth optionality.

The filing also notes notable corporate developments. In February, Michael P. Miller joined Rigel’s Board of Directors as an independent director and member of the Compensation Committee, signaling governance and oversight enhancements. In April, the company received notification from Eli Lilly and Company regarding the termination of a collaboration, the implications of which could ripple through development timelines, milestone timing, and potential upside from in-licensing or partnership-based milestones.

Executive remarks and what they imply

In a statement, Raul Rodriguez, Rigel’s president and CEO, framed the quarter as a proof point of profitability and disciplined financial management. The message emphasizes a strong cash position that can fund development plans and preserve flexibility to pursue in-licensing opportunities. It’s a tone that says: the balance sheet is not just a cushion, it’s a platform for strategic moves—whether that’s advancing R289, maintaining commercial execution, or pivoting when collaboration terms shift.

Outlook and earnings dynamics

The 2026 revenue forecast anchors expectations for growth through a mix of commercial sales and pipeline progression. With net product sales expected to be the primary driver, investors will watch for how RIGL translates this revenue forecast into an EPS trajectory, especially if gross margins, R&D intensity, and potential milestone revenue from collaborations evolve in tandem with the top line.

Analysts may triangulate the reported revenue guidance against any evolving EPS consensus as quarterly results accumulate. The company’s emphasis on a clear revenue target, coupled with strategic pipeline developments, suggests that the stock’s earnings narrative for 2026 will hinge on both execution in commercial markets and the timing of any milestone-driven cash inflows from partnerships or licensing deals.

Implications for Rigel’s peers and the sector

Rigel’s Q1 posture—solid profitability in the face of a developing pipeline and a notable corporate development (board change, collaboration termination)—presents a nuanced yardstick for peers in hematologic disorders and oncology. The steady revenue base from TAVALISSE and Recycler-like performance from GAVRETO and REZLIDHIA signal resilience in this segment, where product sales can support R&D burn and capital-light growth strategies.

In a sector where pipeline timing and strategic partnerships often dictate value, Rigel’s experience with collaboration changes could inform peers’ expectations around milestone timing, collaboration economics, and the optionality of in-licensing discussions. For sector peers, the key takeaway is that a strong quarterly revenue base can coexist with strategic recalibrations in partnerships; the market tends to reward transparent guidance on revenue trajectories and clear milestones for pipeline inflection points.

What to watch next

Upcoming quarterly EPS disclosures and the company’s formal earnings per share computation.
Progress updates on R289 in Phase 1b, including enrollment metrics and dose-selection timing for Phase 2.
Any developments related to the Eli Lilly collaboration termination and its impact on the pipeline and milestones.
Continued execution of commercial plans for TAVALISSE, GAVRETO, and REZLIDHIA and their contributions to the revenue forecast.
Market reaction to the 2026 revenue forecast and how analysts adjust their EPS consensus models.